左乙拉西坦联合丙戊酸钠治疗脑卒中后癫痫的临床效果及安全性

Analysis of clinical efficacy and safety of levetiracetam combined with sodium valproate in the treatment of epilepsy after stroke

目的：探讨左乙拉西坦联合丙戊酸钠治疗脑卒中后癫痫的临床疗效及安全性。方法：选取2015年3月~2016年9月我院收治的脑卒中后癫痫患者80例为研究对象，根据不同治疗方法分为观察组40例，对照组40例，两组患者均接受常规治疗，对照组在常规治疗的基础上给予丙戊酸钠治疗，观察组在常规治疗的基础上给予左乙拉西坦联合丙戊酸钠治疗，观察两组患者的治疗效果、癫痫发作情况及用药后不良反应发生情况。结果：治疗效果显示，观察组总有效率为97％，同对照组的85％比较，差异有统计学意义（P〈0．05）；治疗前，两组患者癫痫发作持续时间及发作次数比较差异无统计学意义（P〉O．05），观察组经治疗后癫痫持续发作时间及发作次数均较对照组少，差异有统计学意义（P〈0．05）；观察组患者用药后，不良反应发生率为22％，同对照组的27％比较，差异无统计学意义（P〉0．05）。结论：左乙拉西坦联合丙戊酸钠治疗脑卒中后癫痫疗效显著，可有效减少癫痫发作次数及发作持续时间，日不增加不良反府。佰得临床府用参考。

Objective：To investigate the clinical efficacy and safety of levetiracetam combined with sodium valproate in the treatment of epilepsy after stroke. Methods：80 patients with epilepsy after stroke hospitalized from March 2015 to September 2016 were selected as the objects and were divided into the observation group and the control group with 40 cases in each group according to different treatment methods. All patients in the two groups were treated with conventional reduction therapy. The patients in the control group were treated with sodium valproate on the basis of conventional treatment while pa- tients in the observation group were treated with levetiracetam combined with sodium valproate on the ba- sis of routine treatment. The curative effect, epileptic seizure and adverse reaction after treatment were observed in the two groups. Results：The total effective rate of the observation group was 97.50%, while it was 85% in the control group, and the difference was statistically significant （P〈0.05）. Before treat- ment, there was no significant difference between the two groups in the duration of seizures and the num- ber of attacks （P〉0.05）. After treatment, the duration of seizures and the number of attacks in the ob- servation group were less than those in the control group, and the difference was statistically significant （P〈0.05）. After medication, the incidence of adverse reactions in the observation group was 22.50%, while it was 27. 50% in the control group, and the difference was not statistically significant （P〉0.05）. Conclusion： Levetiracetarn combined with sodium valproate is an effective therapy in the treatment of epi- lepsy after stroke, which can effectively reduce the frequency of seizures and the duration of attack, and do not increase adverse reactions, worthy of clinical promotion.